MAPT and Alzheimer disease: For instance, Suárez-Calvet et al. (2020) reported CSF p-tau is major prognosis marker in AD as it distinguishes dementia associated with AD from cognitively unimpaired (CU) and MCI, also CSF p-tau is useful for disease staging (Suárez-Calvet et al., 2020).